The DECA® Surgical Glove Series has been developed to meet the diverse and demanding needs of modern surgery:

• DECA® LATEX MICRO – Designed for ultimate precision in microsurgery.
• DECA® LATEX ORTHO – Engineered for the rigorous environment of orthopedic surgery.
• DECA® LATEX STANDARD – Trusted protection and performance for general surgical procedures.
• DECA® NON LATEX – Superior comfort and safety for latex-sensitive surgical needs.

A highlight of the event was the presence of our foreign principal, Mocare Health Co., Ltd., Taiwan, the manufacturer of the DECA® brand. Their collaboration and innovation have been instrumental in bringing this premier product line to life. Our respected Managing Director also graced the occasion, sharing his vision and reaffirming our commitment to excellence in healthcare solutions.

At the heart of the DECA® series lies the revolutionary GDC-Slem Technology. This advanced formulation not only ensures robust hand protection but also actively improves skin texture, reduces roughness, evens tone, and enhances smoothness, setting a new benchmark for both surgical safety and surgeon comfort.

The launch was more than a product introduction. It was a celebration of teamwork and purpose. Alongside insightful sessions, our team enjoyed moments of refreshment, bonding, and creativity, including a vibrant photo booth and group activities. These experiences reinforced our shared mission: to lead the surgical gloves market with innovation, passion, and reliability.

With the DECA® series, ZAS Corporation is not just introducing another product range. We are shaping the future of surgical excellence, where protection meets performance, and safety meets care.

ZAS Corporation is proud to collaborate with the Rheumatology Department of BIRDEM General Hospital to introduce three world-class biosimilar therapies from Celltrion Healthcare, Korea—Yuflyma® (adalimumab), Truxima® (rituximab), and Remsima® (infliximab).
The initiative was formally marked at a recent CME event, where Dr. Sabrina Yesmin, Associate Professor & Head of the Rheumatology Department, shared her expert insights on the role of biosimilars in enhancing treatment accessibility and improving patient outcomes.
This milestone represents a significant step forward in making advanced, evidence-based rheumatology care more affordable and accessible in Bangladesh, aligning global innovation with local healthcare needs.

ZAS Corporation recently organized a series of training sessions across multiple hospitals, engaging ICU nurses on the safe and effective use of noradrenaline in critical care settings. The program focused on practical guidance, updated protocols, and real-world application to support better patient outcomes. Through these interactive sessions, ZAS continues its commitment to enhancing clinical excellence and partnering with healthcare professionals who play a vital role in saving lives every day.

The session highlighted the role of Lyophilized Bacterial Lysates as a promising solution for boosting immunity and reducing the frequency of RTIs in young patients. The event provided a platform for sharing knowledge, exchanging ideas, and fostering collaboration among experts dedicated to advancing pediatric healthcare.

Together, we aim to shape a future where children can thrive in better health. Stay tuned for more initiatives that drive innovation and improve lives!